By Fineline Cube 
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received approval from China’s National Medical Products Administration (NMPA) to conduct a new clinical study for its pipeline drug ZG005. This approval allows the company to evaluate the drug in combination with chemotherapy for the treatment of gastrointestinal tumors, marking another significant step in its oncology development pipeline.
Drug Profile
ZG005 is a first-in-class anti-PD-1/TIGIT bispecific antibody (BsAb) designed for the treatment of solid tumors. The drug’s innovative mechanism targets both PD-1 and TIGIT pathways, enhancing immune response and tumor cell destruction. This dual-target approach addresses the limitations of single-target immunotherapies and offers a novel solution for patients with advanced cancers.
Clinical Trial Progress
Zelgen has previously obtained clinical trial approvals in China for ZG005 in several indications, including advanced biliary tract cancer when combined with platinum, advanced solid tumors, and relapsed refractory lymphomas when combined with jaktinib. The new approval expands the drug’s potential applications and underscores its broad therapeutic potential.-Fineline Info & Tech